fluticasone furoate and vilanterol inhalation powder (Breo Ellipta) (cont.)

Medical Author:
Medical and Pharmacy Editor:

Vilanterol is a bronchodilator of the beta-2 agonist type. Beta-2 agonists are medications that stimulate beta-2 receptors on the smooth muscle cells that surround the airways, causing these muscle cells to relax and thereby opening the airways. It is similar to salmeterol (Serevent). Breo Ellipta opens the airways and increases air supply to the lungs of COPD patients. The FDA approved Breo Ellipta in May 2013.

PRESCRIBED FOR: Breo Ellipta is used for long-term treatment of COPD (emphysema or chronic bronchitis). Breo Ellipta is not used for acute episodes of bronchospasm or treatment of asthma.

SIDE EFFECTS: The most common side effects of Breo Ellipta are:

Breo Ellipta also may cause bronchospasms (wheezing). Bronchospasm should be treated with a rescue inhaler.

High doses of inhaled fluticasone may decrease formation and increase breakdown of bone thereby weakening bones and promoting fractures. Higher doses of fluticasone also may cause suppression of the body's ability to make its own natural glucocorticoid in the adrenal gland. People with suppression of their own adrenal glands (which can be diagnosed by a doctor) would need increased amounts of glucocorticoids, probably by the oral or intravenous route, during periods of high physical stress when glucocorticoids are particularly important.

Medically Reviewed by a Doctor on 5/26/2015

Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Pill Finder Tool

Need help identifying pills and medications?
Use the pill identifier tool on RxList.

Back to Medications Index